Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-24

Study Completion Date

2023-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multi-center randomized trial to assess the safety and performance of low-frequency therapeutic ultrasound for maintaining renal function after contrast exposure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR

NCT01135316

Nephrogenic Systemic Fibrosis

COMPLETED

Delayed Renal Allograft Function and Furosemide Treatment

NCT02312115

Delayed Graft Function

WITHDRAWN PHASE2

Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

NCT05126303

Acute Kidney Injury

TERMINATED PHASE2

Evaluation of Gadoterate in Patients With Renal Dysfunction

NCT02382380

Renal Dysfunction

TERMINATED PHASE4

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

NCT04950114

Kidney Diseases Glomerulosclerosis Focal Segmental Nephrosis +4 more

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, randomized, controlled clinical trial designed to assess the safety and performance of the Sonogenix RENOBOOST as an adjunctive therapy for maintaining renal function after contrast exposure. The trial will enroll up to 234 subjects not taking oral nitrates and at high-risk of developing PC-AKI undergoing coronary arteriography for a planned percutaneous coronary intervention in up to 10 clinical sites in the US and up to 3 clinical sites outside the US.

All subjects will be pre- treated with 0.9 percent NaCl at 3 ml/kg/h 1 hour before and 1 ml/kg/h during and 6 hours post procedure. Participants will be randomized in a 2:1 fashion to either active adjunctive therapy with the Sonogenix RENOBOOST or sham control.

Subjects will have clinical follow-up examination 30 days post index procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contrast-induced Nephropathy Chronic Kidney Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A total of up to 234 participants will be randomized 2:1

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Participant and clinical staff will be blinded to which arm the participant is randomized.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low-Frequency Therapeutic Ultrasound

LOTUS system will be operated per operated per normal instructions

Group Type EXPERIMENTAL

Low-frequency therapeutic ultrasound (LOTUS)

Intervention Type DEVICE

Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.

Sham Control

LOTUS system will be set to Control setting

Group Type SHAM_COMPARATOR

LOTUS System with Ultrasound Disabled

Intervention Type DEVICE

Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low-frequency therapeutic ultrasound (LOTUS)

Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.

Intervention Type DEVICE

LOTUS System with Ultrasound Disabled

Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is greater than or equal to 18 years
* Baseline renal dysfunction defined as one of the following:

1. eGFR greater than 30
2. eGFR 30-45, with or without risk factors for AKI defined as diabetes mellitus, congestive heart failure, proteinuria (defined as albuminuria greater than 300mg/day).
3. eGFR 45-60, with at least one risk factor for AKI defined as diabetes mellitus, congestive heart failure, proteinuria (defined as albuminuria greater than 300mg/day).
* Participant is presenting for a planned percutaneous coronary intervention (PCI)
* Participant scheduled to undergo cardiac catheterization including coronary arteriography that is anticipated to require at least 100 ml of iso-osmolar or low- osmolar contrast, and that is anticipated to include single-vessel stent implantation that does not include chronic total occlusion.
* Participant had not been hospitalized or treated for a change in renal function within 30 days of enrollment.
* Participant has provided written informed consent.
* Participant is willing to comply with study follow-up requirements.

Exclusion Criteria

* Participant is anuric or currently undergoing renal replacement therapy.
* Participant is currently taking oral nitrates.
* Participant is undergoing a procedure requiring selective cannulation and injection of contrast into the renal arteries.
* Participant presented with ST-segment elevation myocardial infarction.
* Participant has a metal implant in the hip or lumbar spine.
* Participant received or is anticipated to receive additional intravenous or intraarterial contrast from 7 days prior to cardiac catheterization to 4 days after cardiac catheterization.
* Addition, discontinuation, or dose change of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, diuretic, trimethoprim, non-steroidal anti-inflammatory drugs, cimetidine, or metoclopramide with 7 days prior to cardiac catheterization.
* Participant has a known allergy to contrast medium that cannot be adequately pre-medicated.
* Participant has new-onset heart failure with New York Heart Association (NYHA) classification of III or IV within 30 days prior to the index procedure.
* Recent stroke within 90 days prior to the index procedure.
* Participant has known or suspected active infection at the time of the index procedure.
* Participant is pregnant and/or breast-feeding or intends to become pregnant during the time of the study.
* Participant is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.
* Participant is known to be incarcerated, mentally incompetent, and/or alcohol or drug abuser.
* Participant is participating in another investigational drug or medical device study that has not completed primary endpoint(s) evaluation or clinically interferes with the endpoints from this study or subject is planning to participate in such studies prior to the completion of this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No